Latest:
Scientists Create Nanoparticle That Helps Fight Solid Tumors
Researchers from Wake Forest University School of Medicine have discovered a possible new approach in treating solid tumors through the creation of a novel nanoparticle.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Yeong “Christopher” Choi, PhD, MBA
Yeong “Christopher” Choi, PhD, MBA, is senior vice president of Industry Partnerships, an associate professor of oncology in the Department of Medicine, and the technical director of the GMP Facility in the Center of Immunotherapy at Roswell Park Comprehensive Cancer Center
Latest:
Dr Choi on the Importance of Education on CAR T-Cell Therapy Manufacturing in Hematologic Malignancies
Yeong “Christopher” Choi, PhD, MBA, discusses importance of product and process education to mitigate variability in CAR T-cell therapy manufacturing in hematologic malignancies.
Vania Hungria, MD, PhD
Latest:
Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
Dr. Vania Hungria presents the Phase 3 DREAMM-7 trial results, demonstrating that belantamab mafodotin, bortezomib, and dexamethasone (BVd) achieved a statistically significant and clinically meaningful overall survival benefit over daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma, with deep, durable responses and manageable safety outcomes.
Sylvia C. Kurz, MD, PhD
Sylvia C. Kurz, MD, PhD, is the interim section chief for Neuro-oncology and co-director of the Chenevert Brain Tumor Center at Yale Cancer Hospital.
Latest:
Dr Kurz on the Efficacy and Safety of Lutetium Lu 177 Dotatate in Advanced Intracranial Meningioma
Sylvia C. Kurz, MD, PhD, discusses the ongoing investigation of the SSTR2-targeting agent 177Lu-DOTATATE in advanced intracranial meningioma.
Katherine (Katie) Tobon, PharmD
Latest:
Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL
Experts discuss their combined experience with cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and other immunotoxicities post chimeric antigen receptor (CAR) T-cell therapy, whether Moffitt Cancer Center implements a standardized protocol to address and resolve cell therapy–associated immunotoxicities, how interventions are modified across grades of severity, and the use of prophylactic strategies to mitigate treatment-related adverse events as well as the roles of the multidisciplinary team in patient monitoring during the initial 30 days and the longer-term postinfusion period.